SUPERNUS PHARMACEUTICALS, INC. (SUPN) Free cash flow 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$46.0MFY2025 · since FY2016: $65.2M → $46.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $46.0M | -73.1% |
| FY2024 | $171.2M | +54.9% |
| FY2023 | $110.5M | -5.1% |
| FY2022 | $116.4M | — |
| FY2020 | $134.9M | -3.9% |
| FY2019 | $140.4M | +9.6% |
| FY2018 | $128.1M | +13.8% |
| FY2017 | $112.6M | +72.7% |
| FY2016 | $65.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross profitSUPN Gross marginSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →